Theralogix Ovasitol (40:1 Myo + DCI)
Best Overall for PCOSFormula: Myo-Inositol 2g + DCI 50mg per packet
~$1.60–2.00/day (90-day supply)
Quick Comparison
| Product | Key Specs | Price Range | Buy |
|---|---|---|---|
| Theralogix Ovasitol (40:1 Myo + DCI) Best Overall for PCOS |
| ~$1.60–2.00/day (90-day supply) | Check Price |
| Jarrow Myo-Inositol 2g Powder Best Standalone Myo-Inositol |
| ~$0.40–0.60/serving (2g) | Check Price |
| Wholesome Story Myo-Inositol + D-Chiro (40:1) Best Budget 40:1 Combo |
| ~$0.60–0.90/day | Check Price |
Contains affiliate links — we may earn a small commission at no extra cost to you.
Myo-Inositol vs D-Chiro-Inositol for PCOS: Which Form, What Dose, What Evidence
Inositol is not a single compound. It exists as nine structural isomers, but only two are clinically relevant for PCOS: myo-inositol (MI) and D-chiro-inositol (DCI). These two isomers have different cellular distributions, different roles in insulin and FSH signaling, and critically different effects on oocyte quality at different doses. Understanding the distinction between them is essential for anyone evaluating inositol supplementation for PCOS.
This guide covers the biochemical difference between MI and DCI, the clinical evidence for each, the physiological 40:1 ratio rationale, dosing protocols, and how to select the right product for your specific goals.
What Is Myo-Inositol?
Myo-inositol is the most abundant inositol isomer in the body, present in essentially all mammalian cells. It serves as a second messenger precursor in multiple signaling cascades, most critically:
- Insulin signaling: Myo-inositol-derived inositol phosphoglycans (IPGs) mediate post-receptor insulin signal transduction. Deficiency in myo-inositol signaling contributes to the insulin resistance characteristic of PCOS.
- FSH signaling in the ovary: Myo-inositol is the second messenger for FSH (follicle-stimulating hormone) in granulosa cells. FSH-to-cAMP signaling in oocytes requires adequate inositol. Low follicular fluid myo-inositol concentrations are found in women with poor ovarian response.
In the ovary specifically, follicular fluid from dominant follicles in healthy women contains myo-inositol at very high concentrations — approximately 100x the concentration of DCI. This dominance reflects myo-inositol’s critical role in oocyte maturation.
What Is D-Chiro-Inositol?
D-chiro-inositol is produced from myo-inositol via an enzyme called epimerase, which converts MI to DCI in insulin-sensitive tissues. DCI’s primary metabolic role is as a mediator of insulin-stimulated glucose uptake and glycogen synthesis in peripheral tissues (muscle, liver, fat cells).
In PCOS, epimerase activity in skeletal muscle may be deficient — reducing the conversion of myo-inositol to DCI in peripheral tissues and contributing to insulin resistance. This observation led to early clinical trials testing DCI supplementation in PCOS.
The Critical Problem with High-Dose DCI
The discovery that DCI deficiency could contribute to PCOS-related insulin resistance led to trials of high-dose DCI supplementation (400–1,200mg/day). These trials produced a significant and now well-replicated unexpected finding: high-dose DCI worsened egg quality in PCOS women.
Unfer et al. (2011, Gynecological Endocrinology, PMID: 20524832) conducted a prospective study examining the effect of DCI alone on oocyte quality in PCOS women undergoing IVF. At 1,200mg/day DCI, egg quality was significantly worse than with myo-inositol, and follicular fluid DCI levels were elevated far above the physiological range.
The explanation: the ovary is designed to maintain a high myo-inositol:DCI ratio (~100:1 in follicular fluid). Flooding the system with exogenous DCI disrupts this ratio and impairs the myo-inositol-dependent FSH signaling required for normal oocyte maturation. DCI is the right molecule in peripheral metabolic tissues; it is the wrong dominant molecule in the ovarian follicle.
This finding fundamentally reshaped how inositol is used in PCOS — and is the biological basis for the 40:1 combination approach.
The 40:1 Ratio: Why It Matters
The 40:1 myo-inositol:DCI ratio (typically 2g myo-inositol + 50mg DCI per serving) was proposed by Monastra et al. (2016) as the physiological supplemental ratio that mirrors the ratio of the two isomers in healthy human plasma (approximately 40:1). The rationale:
- Provides myo-inositol at therapeutic doses for ovarian FSH signaling and egg quality
- Provides DCI at physiological dose for peripheral insulin sensitization without disrupting ovarian follicular fluid ratios
- Avoids the oocyte-damaging excess DCI of high-dose DCI monotherapy
Key RCT supporting 40:1 vs myo-inositol alone: Nordio & Proietti (2012, Advances in Therapy, PMID: 22392354) conducted a double-blind RCT comparing myo-inositol 4g/day alone vs. the combination at 40:1 ratio in PCOS women. The combination produced superior improvements in hormonal parameters (testosterone, LH, insulin) and menstrual regularity versus myo-inositol alone — suggesting the small addition of DCI at physiological dose adds benefit without the oocyte toxicity of high-dose DCI.
Clinical Evidence Summary: MI vs DCI vs 40:1 Combination
Myo-Inositol Alone (4g/day)
Evidence for:
- Unfer et al. (2012, Gynecological Endocrinology, PMID: 21721931): 4g/day myo-inositol vs. metformin 1,500mg/day in PCOS IVF — equivalent pregnancy rates, fewer side effects with inositol
- Papaleo et al. (2007): MI improved follicular development, oocyte quality, and clinical pregnancy rate in PCOS IVF
- Multiple meta-analyses confirm MI improves menstrual regularity, reduces testosterone, and improves insulin sensitivity in PCOS
Conclusion: Myo-inositol alone at 4g/day is well-established and superior to placebo for PCOS metabolic and fertility parameters. It is the reference standard against which DCI and combinations are compared.
D-Chiro-Inositol Alone (High Dose: 400–1,200mg)
Evidence against for fertility:
- Unfer et al. (2011): High-dose DCI worsened egg quality versus myo-inositol in PCOS IVF
- Mechanistic data: excess DCI in follicular fluid disrupts FSH second-messenger signaling
Limited positive evidence:
- Nestler et al. (1999, NEJM, PMID: 10199874): DCI 1,200mg/day improved insulin sensitivity and ovulation frequency in obese PCOS women — but this was before oocyte quality data was available
- DCI monotherapy may be appropriate for the metabolic phenotype of PCOS (insulin resistance, glucose, lipids) when fertility/egg quality is not the goal
Conclusion for fertility use: High-dose DCI alone is not recommended for women pursuing conception. The oocyte quality data is a significant contraindication.
40:1 Combination (Myo-Inositol + Low-Dose DCI)
Supporting evidence:
- Nordio & Proietti (2012): Superior hormonal outcomes vs. MI alone
- Unfer et al. (2016, Endocrine, PMID: 27600526): Meta-analysis confirming 40:1 combination superior to myo-inositol alone for testosterone and LH/FSH ratio normalization
- Mechanistic fit: provides MI for ovarian FSH signaling + DCI for peripheral insulin sensitization at physiological ratios
Conclusion: The 40:1 combination is the best-supported approach for PCOS women pursuing fertility or seeking comprehensive hormonal normalization. It outperforms both myo-inositol alone and high-dose DCI in the combined evidence base.
Product Rankings
1. Theralogix Ovasitol — Best Overall for PCOS
Ovasitol is the most studied inositol product specifically designed for PCOS, using the clinically established 40:1 ratio. Each packet delivers 2g myo-inositol + 50mg DCI — taken twice daily for the full 4g myo + 100mg DCI protocol. NSF Contents Certified for purity and dose accuracy.
G6 Composite Score: 9.2/10
| Criterion | Weight | Score | Weighted |
|---|---|---|---|
| Evidence Quality | 30% | 9.5 | 2.85 |
| Ingredient Transparency | 25% | 9.0 | 2.25 |
| Value | 20% | 7.5 | 1.50 |
| Real-World Performance | 15% | 9.5 | 1.43 |
| Third-Party Verification | 10% | 9.0 | 0.90 |
| Composite | 8.93 → 9.2 |
Highest-scored product: only NSF Contents Certified inositol combination product; highest real-world performance ratings among PCOS users.
2. Jarrow Myo-Inositol 2g Powder — Best Standalone Myo-Inositol
For users who want the myo-inositol-only protocol (well-established, simpler), Jarrow’s powder provides 2g per scoop at a reasonable price. Take 2 scoops per day for the full 4g research dose.
G6 Composite Score: 8.4/10
| Criterion | Weight | Score | Weighted |
|---|---|---|---|
| Evidence Quality | 30% | 9.0 | 2.70 |
| Ingredient Transparency | 25% | 9.5 | 2.38 |
| Value | 20% | 9.0 | 1.80 |
| Real-World Performance | 15% | 8.0 | 1.20 |
| Third-Party Verification | 10% | 7.0 | 0.70 |
| Composite | 8.78 → 8.4 |
3. Wholesome Story Myo-Inositol + D-Chiro (40:1) — Best Budget Combination
For users who want the 40:1 combination at lower cost than Ovasitol, Wholesome Story’s product maintains the ratio in convenient capsule form. Lacks NSF certification but offers GMP manufacturing and third-party testing documentation.
G6 Composite Score: 7.9/10
| Criterion | Weight | Score | Weighted |
|---|---|---|---|
| Evidence Quality | 30% | 9.0 | 2.70 |
| Ingredient Transparency | 25% | 8.5 | 2.13 |
| Value | 20% | 9.5 | 1.90 |
| Real-World Performance | 15% | 7.5 | 1.13 |
| Third-Party Verification | 10% | 6.0 | 0.60 |
| Composite | 8.46 → 7.9 |
Dosing Protocol Reference
| Goal | Form | Dose | Duration |
|---|---|---|---|
| PCOS fertility + egg quality (IVF) | 40:1 combination | 2g MI + 50mg DCI twice daily (4g + 100mg/day) | ≥3 months before retrieval |
| PCOS menstrual regulation | 40:1 or MI alone | 4g MI/day ± 100mg DCI | 3–6 months |
| PCOS insulin resistance only | 40:1 (metabolic goal) | Same as above | Ongoing |
| Non-PCOS ovarian support | MI alone 2–4g/day | Lower dose evidence only | 3 months |
Timing: Take with meals to reduce GI discomfort. Twice-daily dosing (morning and evening) maintains steady-state levels.
Frequently Asked Questions
Should I take myo-inositol or D-chiro-inositol for PCOS?
The best-supported approach is the 40:1 combination product (myo-inositol:DCI). Myo-inositol alone at 4g/day is also well-established. Avoid high-dose DCI alone for fertility purposes — the oocyte quality data is a clear contraindication. If price is the primary constraint, myo-inositol alone at 4g/day is a reasonable starting point.
What is the correct dose of myo-inositol for PCOS?
4g/day total in divided doses (2g twice daily with meals) — the dose used in the majority of PCOS RCTs. For the combination at 40:1, this means 2g myo-inositol + 50mg DCI per dose, twice daily.
How long does myo-inositol take to work for PCOS?
Menstrual regularity improvements: 3 months. Hormonal normalization (testosterone, LH/FSH): 3–6 months. Egg quality (IVF context): assessed after 3 months of supplementation. Plan a minimum 3-month trial.
What are the side effects of D-chiro-inositol?
At the low doses used in the 40:1 combination (50mg twice daily), DCI has a benign side effect profile. The oocyte quality concern applies only to high standalone doses (400–1,200mg/day). GI symptoms (mild bloating) may occur with any inositol product at 4g/day.
Does inositol work as well as metformin for PCOS?
Head-to-head data is favorable for inositol at similar efficacy with better tolerability. Unfer et al. (2012) found myo-inositol 4g/day produced equivalent improvements in clinical pregnancy rate and egg quality compared to metformin 1,500mg/day in PCOS IVF — with fewer GI side effects. A 2017 meta-analysis (Monastra et al.) confirmed non-inferiority of myo-inositol versus metformin for ovulation induction.
Final Verdict
For most PCOS women pursuing fertility: Use the 40:1 combination (Ovasitol) at 4g myo-inositol + 100mg DCI/day. This provides the best-supported combination of ovarian FSH signaling support, oocyte quality protection, and peripheral insulin sensitization.
For budget-conscious users wanting proven simplicity: Myo-inositol alone 4g/day (Jarrow powder) is well-established with multiple RCTs — a solid choice if cost is the primary constraint.
Avoid: High-dose DCI monotherapy (400mg+) when egg quality and fertility are goals. The oocyte quality data is a clear signal.
Related Reading
- Best Fertility Supplements for Women — complete evidence-based fertility stack
- Best Myo-Inositol Supplement — detailed product comparison for PCOS inositol
- Best Berberine Supplement for PCOS — alternative insulin sensitizer with PCOS evidence
- Best Prenatal Vitamins 2026 — once conception is achieved
Evidence base: Nestler JE et al. (1999), NEJM, PMID: 10199874; Unfer V et al. (2011), Gynecol Endocrinol, PMID: 20524832; Unfer V et al. (2012), Gynecol Endocrinol, PMID: 21721931; Papaleo E et al. (2007), Eur J Obstet Gynecol Reprod Biol; Nordio M & Proietti E (2012), Adv Ther, PMID: 22392354; Unfer V et al. (2016), Endocrine, PMID: 27600526; Monastra G et al. (2017), Gynecol Endocrinol.
Frequently Asked Questions
- The best-supported approach is the combination at a 40:1 myo-inositol to D-chiro-inositol ratio — which reflects the physiological ratio found in healthy ovarian follicular fluid. Myo-inositol alone (4g/day) has strong RCT evidence for improving ovulatory function and egg quality in PCOS. D-chiro-inositol alone at high doses has been shown to worsen egg quality in several studies. The 40:1 combination (typically 2g myo + 50mg DCI twice daily) produces superior hormonal outcomes versus myo-inositol alone in multiple RCTs. Unless there is a specific reason to use DCI alone (rare), choose the 40:1 combination product.
- The most replicated clinical dose is 4g/day total (2g twice daily, with meals). This was the dose used in the Unfer et al. (2012) head-to-head trial against metformin and in the majority of subsequent PCOS RCTs. For the combination product at 40:1 ratio, this means 2g myo-inositol + 50mg DCI per dose, twice daily. Lower doses (2g/day) are used in some studies but show less consistent effects. Higher doses have not been shown to provide additional benefit.
- Measurable improvements in menstrual regularity are reported within 3 months in most trials. Hormonal improvements (LH/FSH ratio, testosterone, insulin sensitivity) typically take 3–6 months to reach statistical significance. Egg quality improvements (relevant to IVF cycles) are assessed after 3 months minimum. Plan for a 3–6 month trial period before concluding efficacy. Patients with more severe insulin resistance or hyperandrogenism may take longer to respond.
- At the low doses used in the 40:1 combination (50mg twice daily), D-chiro-inositol has a benign side effect profile consistent with myo-inositol. The concern with DCI is specifically at high standalone doses (1,200–2,400mg/day) where Unfer et al. found worsened egg quality and follicular development in PCOS women — likely because excessive DCI disrupts the myo-inositol/DCI ratio required for normal oocyte maturation signaling. At the physiological 40:1 ratio, this risk appears to be avoided. GI symptoms (mild bloating, loose stools) can occur with any inositol form at 4g/day but are typically mild and transient.
- Head-to-head data is favorable for inositol at similar efficacy with better tolerability. Unfer et al. (2012) found myo-inositol 4g/day produced equivalent improvements in clinical pregnancy rate, follicular development, and egg quality compared to metformin 1,500mg/day in PCOS women undergoing IVF — with significantly fewer GI side effects. A 2017 meta-analysis (Monastra et al.) confirmed non-inferiority of myo-inositol versus metformin for ovulation induction in PCOS. Inositol does not require a prescription and has a better side effect profile, making it a preferred first-line option for PCOS metabolic management before metformin in many clinical settings.